These high-degree protein targets may be the key targets such as neurotrophic receptor tyrosine kinase 1, nuclear receptor subfamily 3 group C member 1, cyclin D1, erb-B2 receptor tyrosine kinase 2, and account for the essential therapeutic effects of CWT on insomnia. The gene discussed is NTRK1; the disease is insomnia measurement.